Targeted Strategies for Today's Evolving Markets

MissionIR Blog

FluoroPharma Medical, Inc. (FPMI) Presents Products at Two Major Scientific Forums, Raises Revenue Forecast

FluoroPharma Medical, a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, recently announced a considerable increase in its revenue forecast.

Thijs Spoor, Chairman, CEO, and President of FluoroPharma Medical, made the announcement during his presentation at the Rodman & Renshaw Annual Global Investment Conference in New York City. Mr. Spoor noted that the decision to increase the revenue estimate reflected growing confidence in the strength of the company’s portfolio.

The pivotal event that spurred this increase was, in large part, due to FluoroPharma’s diagnostic imaging products being included at two major scientific forums. The company announced that, on September 7, 2012, its BFPET images were presented at the 17th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC) at the Mario Verani Lecture. Dr. Gary V. Heller included the images in his lecture on “Nuclear Cardiology in 2012 and Beyond: Can we Meet the Challenges?”

Additionally, FluoroPharma noted that two abstracts describing its products were presented as posters at the World Molecular Imaging Congress, held in Dublin Ireland.

“Our initial focus is on cardiology, the largest segment of the nuclear medicine market,” noted Mr. Spoor. “As our products advance through clinical trials, we are even more confident that we have three significant opportunities in this critically important market. Molecular imaging fulfills numerous unmet diagnostic needs by enabling visualization, characterization and measurement of biological processes at the molecular and cellular level.” Mr. Spoor continued, saying, “Unlike the traditional imaging modalities of MRI, CT and ultrasound, which reveal anatomical abnormalities, PET provides insight into physiology and can detect disease before an anatomical manifestation is identified. The combination of both modalities is becoming a more powerful tool; helping doctors address the question, ‘What do I do next for this patient?’”

For more information on FluoroPharma Medical, visit

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

* Copy This Password *

* Type Or Paste Password Here *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>